Latest Temozolomide Stories
SEATTLE, Nov. 22, 2010 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
Data presented today from a pivotal, phase III randomized clinical trial for patients with recurrent glioblastoma tumors suggest that Tumor Treating Fields (TTF) therapy may increase median survival time and improve quality of life scores compared to best standard of care chemotherapy.
A new vaccine added to standard therapy appears to offer a survival advantage for patients suffering from glioblastoma (GBM), the most deadly form of brain cancer.
CHICAGO, June 5 /PRNewswire/ -- Data from the first phase III clinical trial of NovoCure's NovoTTF device for treatment of patients with recurrent glioblastoma (GBM) were presented today as a late breaking abstract during the Neuro-Oncology session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
MISSISSAUGA, May 21 /PRNewswire-FirstCall/ - YM BioSciences Inc.
Small molecule plus TMZ appears to lower tumor resistance.
MALVERN, Pa., Oct.
Chemotherapy alone is just as effective as radiation / New positive prognostic factor found.
NEW YORK, Sept. 28 /PRNewswire/ -- NovoCure, Ltd., a privately held medical device company focused on developing the Novo-TTF device, a non-invasive portable medical device for the treatment of cancer, announced the completion of a new funding round today.
- a meat pie that is usually eaten at Christmas in Quebec